PLUS1
58.00
-0.87 (-1.48%)
-0.87 (-1.48%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| uniQure NV | QURE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -2.49 | -4.06% | 58.87 | 58.19 | 62.35 | 61.61 | 61.36 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 57.29 | 106.87 | 49.58 | 46.39% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,218 | 360,519 | $ 59.72 | $ 21,530,474 | 406,271 | 36.20 - 82.49 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:29:46 | 60 | $ 58.00 | USD |
uniQure NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 2.61B | 44.30M | 39.61M | $ 7.28M | $ - | -3.12 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
uniQure NV News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/22/2020 | 17:14 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/14/2020 | 16:46 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/14/2020 | 07:00 | GlobeNewswire Inc. | uniQure Presents New Preclinical Data in SCA3, Fabry.. |
| 4/29/2020 | 17:26 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 4/29/2020 | 07:00 | GlobeNewswire Inc. | uniQure Announces First Quarter 2020 Financial Results and.. |
| 4/29/2020 | 06:49 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 4/29/2020 | 06:11 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QURE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 63.00 | 67.50 | 58.19 | 65.34 | 333,540 | -4.13 | -6.56% |
| 1 Month | 61.99 | 67.96 | 55.21 | 62.06 | 352,411 | -3.12 | -5.03% |
| 3 Months | 42.93 | 67.96 | 37.50 | 55.18 | 361,853 | 15.94 | 37.13% |
| 6 Months | 65.13 | 76.6869 | 37.50 | 60.72 | 438,592 | -6.26 | -9.61% |
| 1 Year | 71.17 | 82.49 | 36.20 | 59.79 | 535,459 | -12.30 | -17.28% |
| 3 Years | 5.49 | 82.49 | 4.90 | 42.44 | 458,413 | 53.38 | 972.31% |
| 5 Years | 29.65 | 82.49 | 4.72 | 34.62 | 383,271 | 29.22 | 98.55% |
uniQure NV Description
| uniQure NV is a gene therapy company. It develops treatment and platform for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers-Squibb for cardiovascular diseases. |
